This trial looks at how well rilvegostomig works with chemotherapy compared to pembrolizumab with chemotherapy. It focuses on patients with metastatic squamous non-small cell lung cancer (NSCLC) whose tumors show a certain marker called PD-L1. The goal is to find out which treatment helps patients the most as a first-line option.
This is a Phase 3 trial, which means it is looking at how well the treatments work and how safe they are. The trial hopes to include about 880 participants and is FDA-regulated.
Who can join
Adults aged 18 and older can join this trial. It is open to all men and women who have been diagnosed with squamous NSCLC that has spread and cannot be cured. There are some health conditions that may prevent someone from joining. The trial team will confirm if you are eligible before you can participate.
Condition
Non-small Cell Lung Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will receive rilvegostomig with chemotherapy, while the other group will get pembrolizumab with chemotherapy. Everyone will receive treatment through IV (intravenous) infusions on specific days of each 21-day cycle. This trial aims to measure how long patients live and how well their cancer is controlled.
Where
This trial is enrolling at 74 locations. Recruiting sites are listed first.
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.